Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM6 | O15303 | 1/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.51 |
| ▸ | GRM3 | Q14832 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563355 | 1.00 | GRM6 (0.53) | GRM6GRM2GRM3 | |
| SCHEMBL4662615 | 1.00 | GRM6 (0.53) | GRM6GRM2GRM3 | |
| SCHEMBL5567570 | 1.00 | GRM6 (0.53) | GRM6GRM2GRM3 | |
| SCHEMBL8973083 | 0.85 | GRM2 (0.58) | GRM6GRM2GRM3 | |
| SCHEMBL5566641 | 0.83 | GRM2 (0.44) | GRM6GRM2GRM3 | |
| SCHEMBL4663771 | 0.81 | GRM2 (0.50) | GRM6GRM2GRM3 | |
| SCHEMBL5561558 | 0.81 | GRM2 (0.50) | GRM6GRM2GRM3 | |
| SCHEMBL5567019 | 0.81 | GRM2 (0.50) | GRM6GRM2GRM3 | |
| SCHEMBL4662147 | 0.81 | GRM2 (0.50) | GRM6GRM2GRM3 | |
| SCHEMBL5567527 | 0.79 | GRM2 (0.49) | GRM6GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | FAUST PHARMACEUTICALS (FR) | 2008-01-31 | — | — | US | claimed |
| EP-1751098-A1 | TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE | Faust Pharmaceuticals (FR) | 2007-02-14 | — | — | EP | claimed |
| WO-2005118533-A1 | TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE | FAUST PHARMACEUTICALS (FR) | 2005-12-15 | — | — | WO | claimed |
| EP-1604978-A1 | Trans pyrrolidinyl derivatives and their pharmaceutical uses | Faust Pharmaceuticals (FR) | 2005-12-14 | — | — | EP | claimed |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | FAUST PHARMACEUTICALS (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | FAUST PHARMACEUTICALS (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | FAUST PHARMACEUTICALS (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1751098-A1 | TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE | Faust Pharmaceuticals (FR) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118533-A1 | TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE | FAUST PHARMACEUTICALS (FR) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118533-A1 | TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE | FAUST PHARMACEUTICALS (FR) | 2005-12-15 | — | — | WO | disclosed |
| EP-1604978-A1 | Trans pyrrolidinyl derivatives and their pharmaceutical uses | Faust Pharmaceuticals (FR) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | SUCNR1, GLRA1, CNR1 | GRM6 77/4885GRM2 47/4885GRM3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.